[Gilteritinib (AML) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003654
German
Original Title:
Gilteritinib (rezidivierte oder refraktaere akute myeloische Leukaemie) - Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/g19-20.html
Year Published:
2020
URL for published report:
https://www.iqwig.de/download/G19-20_Gilteritinib_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Leukemia, Myeloid, Acute
- fms-Like Tyrosine Kinase 3
- Antineoplastic Agents
Keywords
- Gilteritinib
- Leukemia - Myeloid - Acute
- Health Care Costs
- Epidemiology
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.